144,000 Shares in I-Mab (NASDAQ:IMAB) Purchased by Garden State Investment Advisory Services LLC

Garden State Investment Advisory Services LLC bought a new position in I-Mab (NASDAQ:IMAB) during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm bought 144,000 shares of the company’s stock, valued at approximately $179,000. Garden State Investment Advisory Services LLC owned about 0.18% of I-Mab as of its most recent SEC filing.

Separately, Caligan Partners LP lifted its holdings in I-Mab by 3.7% in the third quarter. Caligan Partners LP now owns 3,499,330 shares of the company’s stock worth $4,339,000 after acquiring an additional 124,539 shares during the last quarter. 38.38% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reissued a “buy” rating and issued a $8.00 target price on shares of I-Mab in a report on Friday, November 15th.

I-Mab Price Performance

Shares of NASDAQ IMAB opened at $0.98 on Tuesday. The firm’s 50-day moving average price is $1.17 and its two-hundred day moving average price is $1.35. I-Mab has a 52-week low of $0.90 and a 52-week high of $2.54.

I-Mab Company Profile

I-Mab, a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics in the fields of immuno-oncology and immuno-inflammation diseases primarily in the United States. It is developing Uliledlimab, a CD73 neutralizing antibody, which is in Phase 2 clinical trial for the treatment of solid tumors; Givastomig, a bi-specific antibody that is in Phase 1 clinical trial for the treatment of gastric and other cancers; and Ragistomig, a programmed cell death ligand-based tumor-dependent T cell engager, which is in Phase 1 clinical trial for the treatment of for solid tumors.